Sundar Jagannath

62.0k total citations · 3 hit papers
626 papers, 21.2k citations indexed

About

Sundar Jagannath is a scholar working on Hematology, Molecular Biology and Oncology. According to data from OpenAlex, Sundar Jagannath has authored 626 papers receiving a total of 21.2k indexed citations (citations by other indexed papers that have themselves been cited), including 529 papers in Hematology, 319 papers in Molecular Biology and 303 papers in Oncology. Recurrent topics in Sundar Jagannath's work include Multiple Myeloma Research and Treatments (498 papers), Protein Degradation and Inhibitors (215 papers) and Cancer Treatment and Pharmacology (95 papers). Sundar Jagannath is often cited by papers focused on Multiple Myeloma Research and Treatments (498 papers), Protein Degradation and Inhibitors (215 papers) and Cancer Treatment and Pharmacology (95 papers). Sundar Jagannath collaborates with scholars based in United States, Canada and France. Sundar Jagannath's co-authors include Bart Barlogie, Guido Tricot, David S. Siegel, David H. Vesole, Kenneth C. Anderson, Paul G. Richardson, Amitabha Mazumder, John Crowley, Sagar Lonial and Nikhil C. Munshi and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and The Journal of Experimental Medicine.

In The Last Decade

Sundar Jagannath

603 papers receiving 20.6k citations

Hit Papers

High-Dose Therapy and Autologous Bone Marrow Transplantat... 1987 2026 2000 2013 1987 2004 1988 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. High-Dose Therapy and Autologous Bone Marrow Transplantation after Failure of Conventional Chemotherapy in Adults with Intermediate-Grade or High-Grade Non-Hodgkin's Lymphoma
    1987 642 citations Sundar Jagannath et al. profile →
  2. A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma
    2004 569 citations Sundar Jagannath, Bart Barlogie et al. profile →
  3. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP)
    1988 487 citations Sundar Jagannath et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sundar Jagannath United States 76 13.9k 10.8k 10.7k 3.0k 2.6k 626 21.2k
Hartmut Goldschmidt Germany 68 12.5k 0.9× 8.0k 0.7× 10.1k 0.9× 1.9k 0.7× 1.4k 0.5× 660 18.4k
Guido Tricot United States 82 16.0k 1.2× 7.9k 0.7× 10.9k 1.0× 2.7k 0.9× 1.5k 0.6× 463 22.3k
Rafaël Fonseca United States 84 17.5k 1.3× 9.9k 0.9× 16.2k 1.5× 1.8k 0.6× 3.7k 1.4× 441 25.8k
Mario Boccadoro Italy 60 10.9k 0.8× 7.4k 0.7× 8.3k 0.8× 2.5k 0.8× 1.7k 0.6× 479 15.9k
Martha Q. Lacy United States 78 15.8k 1.1× 9.4k 0.9× 16.8k 1.6× 1.7k 0.6× 2.0k 0.8× 554 25.4k
Jean‐Luc Harousseau France 69 11.0k 0.8× 7.0k 0.6× 8.8k 0.8× 1.5k 0.5× 2.2k 0.8× 319 15.8k
Philip R. Greipp United States 85 18.0k 1.3× 10.9k 1.0× 17.5k 1.6× 2.5k 0.8× 2.7k 1.0× 323 28.4k
Thierry Façon France 69 17.1k 1.2× 10.6k 1.0× 13.1k 1.2× 1.5k 0.5× 1.3k 0.5× 458 21.9k
Hervé Avet‐Loiseau France 67 12.7k 0.9× 7.4k 0.7× 11.3k 1.1× 1.4k 0.5× 1.9k 0.7× 374 17.0k
Michel Attal France 66 13.2k 1.0× 7.4k 0.7× 8.4k 0.8× 1.8k 0.6× 1.5k 0.6× 322 16.2k

Countries citing papers authored by Sundar Jagannath

Since Specialization
Citations

This map shows the geographic impact of Sundar Jagannath's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sundar Jagannath with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sundar Jagannath more than expected).

Fields of papers citing papers by Sundar Jagannath

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sundar Jagannath. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sundar Jagannath. The network helps show where Sundar Jagannath may publish in the future.

Co-authorship network of co-authors of Sundar Jagannath

This figure shows the co-authorship network connecting the top 25 collaborators of Sundar Jagannath. A scholar is included among the top collaborators of Sundar Jagannath based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sundar Jagannath. Sundar Jagannath is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Aleman, Adolfo, Erin Moshier, Adriana Rossi, et al.. (2025). Clonal Hematopoiesis and Inflammation Predict Hematologic Toxicity and Secondary Myeloid Malignancies after B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T-cell Therapy. Clinical Cancer Research. 31(20). 4333–4344. 1 indexed citations
2.
Gold, Julie, Alessandro Laganà, Kenan Onel, et al.. (2024). FaMMily Affairs: Dissecting inherited contributions to multiple myeloma risk. Seminars in Hematology. 62(1). 11–19. 1 indexed citations
3.
Coffey, David G., Keren Osman, Adolfo Aleman, et al.. (2024). Phase 1 study combining elotuzumab with autologous stem cell transplant and lenalidomide for multiple myeloma. Journal for ImmunoTherapy of Cancer. 12(4). e008110–e008110. 5 indexed citations
4.
Chen, Lucia, Santiago Thibaud, Ajai Chari, et al.. (2024). MRD-negative duration following latest line of therapy predicts long-term PFS in real-world patients with multiple myeloma. Blood Advances. 9(1). 176–179.
5.
Lin, Yi, Thomas Martin, Saad Z. Usmani, et al.. (2023). POSTER: MM-309 CARTITUDE-1 Final Results: Phase 1b/2 Study of Ciltacabtagene Autoleucel in Heavily Pretreated Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 23. S226–S226. 1 indexed citations
6.
Lancman, Guido, Lisa Avery, Hearn Jay Cho, et al.. (2023). IVIg Use Associated with Ten-Fold Reduction of Serious Infections in Multiple Myeloma Patients Treated with Anti-BCMA Bispecific Antibodies. Blood Cancer Discovery. 4(6). 440–451. 56 indexed citations
7.
Sindhu, Kunal K., Erin Moshier, Joshua Richter, et al.. (2021). The Safety and Efficacy of Radiation Therapy with Concurrent Dexamethasone, Cyclophosphamide, Etoposide, and Cisplatin-Based Systemic Therapy for Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 22(3). 192–197. 6 indexed citations
8.
Raje, Noopur, David S. Siegel, Sundar Jagannath, et al.. (2021). Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of High-Risk Subgroups in the KarMMa Study. Transplantation and Cellular Therapy. 27(3). S66–S67. 2 indexed citations
9.
Berdeja, Jesús G., Noopur Raje, David S. Siegel, et al.. (2021). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel, bb2121) in Elderly Patients with Relapsed and Refractory Multiple Myeloma: KarMMa Subgroup Analysis. Transplantation and Cellular Therapy. 27(3). S397–S398. 2 indexed citations
10.
Perumal, Deepak, Naoko Imai, Alessandro Laganà, et al.. (2019). Mutation-derived Neoantigen-specific T-cell Responses in Multiple Myeloma. Clinical Cancer Research. 26(2). 450–464. 59 indexed citations
11.
Cooper, Dennis, Deepu Madduri, Suzanne Lentzsch, et al.. (2019). Safety and Preliminary Clinical Activity of REGN5458, an Anti-Bcma x Anti-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 134(Supplement_1). 3176–3176. 31 indexed citations
12.
Laganà, Alessandro, David T. Melnekoff, Violetta V. Leshchenko, et al.. (2017). Clonal Evolution in Newly Diagnosed Multiple Myeloma Patients: A Follow-up Study from the Mmrf Commpass Genomics Project. Blood. 130. 325–325. 2 indexed citations
13.
14.
Yanamandra, Uday, Navin Khattry, Shaji Kumar, et al.. (2017). Consensus in the Management of Multiple Myeloma in India at Myeloma State of the Art 2016 Conference. Indian Journal of Hematology and Blood Transfusion. 33(1). 15–21. 12 indexed citations
15.
Siegel, David S., Katja Weisel, Meletios Α. Dimopoulos, et al.. (2016). Pomalidomide plus low-dose dexamethasone in patients with relapsed/refractory multiple myeloma and moderate renal impairment: a pooled analysis of three clinical trials. Leukemia & lymphoma. 57(12). 2833–2838. 21 indexed citations
16.
Perumal, Deepak, Violetta V. Leshchenko, Zewei Jiang, et al.. (2016). Dual Targeting of CDK4 and ARK5 Using a Novel Kinase Inhibitor ON123300 Exerts Potent Anticancer Activity against Multiple Myeloma. Cancer Research. 76(5). 1225–1236. 27 indexed citations
17.
Kurzrock, Razelle, Peter M. Voorhees, Corey Casper, et al.. (2013). A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease. Clinical Cancer Research. 19(13). 3659–3670. 166 indexed citations
18.
Jakubowiak, Andrzej, Dominik Dytfeld, Kent A. Griffith, et al.. (2012). A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood. 120(9). 1801–1809. 311 indexed citations
19.
Jagannath, Sundar, Meletios Α. Dimopoulos, & Sagar Lonial. (2010). Combined proteasome and histone deacetylase inhibition: A promising synergy for patients with relapsed/refractory multiple myeloma. Leukemia Research. 34(9). 1111–1118. 43 indexed citations
20.
Barlogie, Bart, Sundar Jagannath, S. Naucke, et al.. (1998). Long-term follow-up after high-dose therapy for high-risk multiple myeloma. Bone. 1101–11071. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hartmut Goldschmidt Breakdown of academic impact, for papers by Guido Tricot Breakdown of academic impact, for papers by Rafaël Fonseca Breakdown of academic impact, for papers by Mario Boccadoro Breakdown of academic impact, for papers by Martha Q. Lacy Breakdown of academic impact, for papers by Jean‐Luc Harousseau Breakdown of academic impact, for papers by Philip R. Greipp Breakdown of academic impact, for papers by Thierry Façon Breakdown of academic impact, for papers by Hervé Avet‐Loiseau Breakdown of academic impact, for papers by Michel Attal
Rankless by CCL
2026